Tokyo continued a three-week upturn in the review period to June 8. The Nikkei 225 was up 1.9% to close at 9865.63, a new eight-month high, while the Topix Index rose 1.6%. There was persistent hope for an early economic recovery in Japan, fueled by a positive comment from the Japanese Finance Minister that the economy had bottomed-out during the January-March quarter. However, investors saw a dearth of fresh domestic incentives and realized that the recent Japanese market development was largely influenced by external factors and news, such as the start of US car maker General Motor's initiation of reconstruction under government backing, as well as foreign exchanges. Reflecting the yen's fall, export-oriented issues drew buying attention. The pharmaceutical index ended down 2.8%, underperforming the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze